+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

BRCA1 and BRCA2 founder mutations account for 78% of germline carriers among hereditary breast cancer families in Chile



BRCA1 and BRCA2 founder mutations account for 78% of germline carriers among hereditary breast cancer families in Chile



Oncotarget 8(43): 74233-74243



Identifying founder mutations in BRCA1 and BRCA2 in specific populations constitute a valuable opportunity for genetic screening. Several studies from different populations have reported recurrent and/or founder mutations representing a relevant proportion of BRCA mutation carriers. In Latin America, only few founder mutations have been described. We screened 453 Chilean patients with hereditary breast cancer for mutations in BRCA1 and BRCA2. For recurrent mutations, we genotyped 11 microsatellite markers in BRCA1 and BRCA2 in order to determine a founder effect through haplotype analysis. We found a total of 25 mutations (6 novel) in 71 index patients among which, nine are present exclusively in Chilean patients. Our analysis revealed the presence of nine founder mutations, 4 in BRCA1 and 5 in BRCA2, shared by 2 to 10 unrelated families and spread in different regions of Chile. Our panel contains the highest amount of founder mutations until today and represents the highest percentage (78%) of BRCA1 and BRCA2 mutation carriers. We suggest that the dramatic reduction of Amerindian population due to smallpox and wars with Spanish conquerors, a scarce population increase during 300 years, and the geographic position of Chile constituted a favorable scenario to establish founder genetic markers in our population.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 059821130

Download citation: RISBibTeXText

PMID: 29088781

DOI: 10.18632/oncotarget.18815


Related references

High frequency of pathogenic non-founder germline mutations in BRCA1 and BRCA2 in families with breast and ovarian cancer in a founder population. Hereditary Cancer in Clinical Practice 16: 12, 2018

Founder BRCA1 mutations and two novel germline BRCA2 mutations in breast and/or ovarian cancer families from North-Eastern Poland. Human Mutation 15(5): 480-481, 2000

BRCA1 and BRCA2 Germline Mutations in Japanese with Hereditary Breast Cancer Families. Breast Cancer 4(4): 256-258, 2000

Ashkenazi founder BRCA1/BRCA2 mutations in Slovak hereditary breast and/or ovarian cancer families. Neoplasma 53(2): 97-102, 2006

Prevalence of BRCA1 and BRCA2 founder mutations in Brazilian hereditary breast and ovarian cancer families. Journal of Clinical Oncology 26(15_Suppl): 22108-22108, 2016

BRCA1, BRCA2 and CHEK2 (1100 del C) germline mutations in hereditary breast and ovarian cancer families in South India. Asian Pacific Journal of Cancer Prevention 4(3): 203-208, 2003

Immunohistochemical characteristics defined by tissue microarray of hereditary breast cancer not attributable to BRCA1 or BRCA2 mutations: differences from breast carcinomas arising in BRCA1 and BRCA2 mutation carriers. Clinical Cancer Research 9(10 Pt 1): 3606-3614, 2003

Screening for germline BRCA1, BRCA2, TP53 and CHEK2 mutations in families at-risk for hereditary breast cancer identified in a population-based study from Southern Brazil. Genetics and Molecular Biology 39(2): 210-222, 2016

BRCA1 and BRCA2 analysis in breast cancer families from Sardinia Identification of two BRCA2 founder mutations with their clinical and pathological implications. European Journal of Cancer 37(Suppl. 6): S176, 2001

BRCA1 and BRCA2 germline mutations in Sardinian breast cancer families. Journal of Clinical Oncology 24(18_Suppl): 20118-20118, 2016

BRCA1 and BRCA2 germline mutations in Uruguayan breast and breast-ovarian cancer families. Identification of novel mutations and unclassified variants. Breast Cancer Research and Treatment 128(1): 211-218, 2011

Germline Brca1/Brca2 Mutations in Breast/ovarian Cancer Families in Croatia: Identification of Three Novel Mutations. European Journal of Cancer 48: S274-S275, 2012

Fifty percent of Jewish high-risk breast and ovarian cancer families are not explained by the three known BRCA1 or BRCA2 founder mutations while a 07 percent combined BRCA1 founder mutation frequency is reported in a Jewish cohort. American Journal of Human Genetics 59(4 Suppl. ): A28, 1996

Founder BRCA1 and BRCA2 mutations in French Canadian breast and ovarian cancer families. American Journal of Human Genetics 63(5): 1341-1351, 1998

Double PALB2 and BRCA1/BRCA2 mutation carriers are rare in breast cancer and breast-ovarian cancer syndrome families from the French Canadian founder population. Oncology Letters 9(6): 2787-2790, 2015